Through investments made by the Bipartisan Safer Communities Act (BSCA), the grants will be awarded to 20 states of up to $2.5 million to support the implementation, improvement and expansion of school-based health services through Medicaid and the Children’s Health Insurance Program (CHIP).
CMS said in a news release today that 13.7 million beneficiaries are in accountable care organizations (ACOs) and that a total of 480 ACOs are participating in the Medicare Shared Savings Program (MSSP).
CVS Caremark, however, will continue to manage specialty drug benefits for Tyson Foods.
Data from 17 longitudinal studies of adults with HIV treated with antiretroviral therapy how that proportion of deaths caused by AIDS has fallen from nearly 50% to 16% and that all-cause mortality has been sliced in half.
Adherent patients accessed services only slightly more.
After the overturn of Roe V. Wade, states with ban see less than a dozen legal abortions a month.
The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.
Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.
Experts from Harvard, Georgetown and Johns Hopkins debate the wisdom of cost sharing in today's JAMA Internal Medicine.
A research team led by University of California, San Francisco, found flaws in how the large language model assessed prevalence and made differential diagnoses.
The FDA approved Dermavant Science's Vtama (tapinarof cream) last year as a treatment for plaque psoriasis. Sales have been disappointing, according to press reports. Will Vtama, which has a different mechanism of action than the current batch of topical medications for atopic dermatitis, fare better in the atopic dermatitis market?
The outlook for leukemia patients improved after Gleevec (imatinib) was approved in 2001 as a treatment for chronic myeloid leukemia. The American Cancer Society published its annual cancer statistics report today that projects 62,770 new cases of leukemia will be diagnosed this year and 23,670 deaths from the disease will occur.
Annual report from the American Cancer Society says HIV is an underlying factor in a handful of cancer diagnoses.
The proportion of cancer patients who are 50-64 is increasing while the proportion of those 65 and older is shrinking, according to American Cancer Society researchers.
Overall cancer mortality in the U.S. continues to decline but there are some worrying trends in incidence and wide racial disparities.
States can use federal money that would otherwise support ACA marketplace premium tax credits to set up programs that offer health insurance to low-income people whose incomes are too high to make them eligible for Medicaid.
The smartphone app is currently under investigation in the CONVOKE study as a pharmaceutical therapy, aiming to address the negative symptoms associated with adult schizophrenia.
A substantial reduction in claim costs can be persuasive and attention-grabbing, but without assurances of continuity of care and proper clinical oversight, the ultimate goal of positive patient health outcomes can be elusive — and costly.
The CAR T-cell therapy targets the CD19 protein ubiquitous on the surface of B cells, which are known to mediate various types of autoimmune diseases, including MS.
UnitedHealth Group executives attribute the increase of revenue at Optum Rx to the addition of new clients, expanded relationships with existing clients, and advancements in services.
UnitedHealth Group executives attribute the increase in revenue and earnings to growth at both its Optum and UnitedHealthcare divisions.
Researchers developed a new multi-cancer blood screening test to detect early-stage cancers and found it had a high level of accuracy.
Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.
New sign-up rates for plan selections total 18%.
